

# Mirae Asset Nifty 500 Healthcare ETF

(An open-ended scheme replicating/tracking Nifty500 Healthcare Total Return Index)

---

## ETF New Fund Offer details:


New Fund Offer (NFO) starts on: 27<sup>th</sup> January, 2026

New Fund Offer (NFO) closes on: 06<sup>th</sup> February, 2026

Scheme re-opens on: 11<sup>th</sup> February, 2026



# Healthcare Industry in India



# Key Components of Indian Healthcare Sector

## Medical Equipment & Supplies

Covers manufacturing and supply of medical devices and diagnostic equipment; valued at US\$15.3 billion in 2023.



## Healthcare Research, Analytics & Technology

Covers purification, separation, filtration, and chromatography; projected to grow at a ~15.8% CAGR from 2025–2030 to reach ~US\$3.1 billion by 2030.



## Hospital

Includes healthcare centres, district/general hospitals, and nursing homes; attracted FDI inflows US\$1.5 billion in FY 2024.



## Healthcare Service Provider

Covers businesses and laboratories, including stand-alone & hospital labs as well as diagnostic services; market size at ~US\$9.8 billion in FY 2024.




## Pharmaceuticals


Covers manufacturing and export of generics, APIs, vaccines, and biopharma to 150+ countries; market size at US\$55 billion in 2025.

# Healthcare Sector in India: Where are we?

India's public healthcare market was USD 130 bn in 2024.....\*



## Government Healthcare Expenditure (as % of GDP)



Healthcare market is growing fast, reached \$130B in 2024, supported by steady government spending



# India – Poised to become pharmacy of the world



Accounts for  
**~60%**  
of global vaccine supplies

**3<sup>rd</sup>** Largest  
market by volume




**12<sup>th</sup>** largest  
exporter of medical  
goods in the world




Generic drugs account for  
**20%** of the global export  
in terms of volume

Indian Pharmaceutical Market (US\$ billion)



India's Pharmaceuticals Exports (\$ billion)



# Pharma Growth Story: The building blocks




PLI scheme: ₹15,000 crore (US\$2.04 billion) outlay (2020–2029) to boost pharma manufacturing and investment.

The sector received FDI inflow of Rs. 2,10,940 crore (US\$ 24.62 billion) from April 2000-June 2025.

Under PMBJP, 16,912 Jan Aushadhi Kendras offer 2,110 medicines and 315 devices, with a target of 25,000 outlets by March 2027 to promote affordable generic healthcare.


Union Budget 2025-26: ₹5,268 crore (US\$602 million) allocated to the Department of Pharmaceuticals, up 28.8% from last year.

# Pharma Growth Story: The export lever




# Hospitals: Infrastructure, expansion, medical tourism


.....with private and trust hospitals holding 67% of the Hospitals market



Indian medical tourism market (USD billion)



Hospital Bed Capacity Growth (FY19–FY27P)




Hospital market and medical tourism are expanding at double-digit growth rates, supported by ongoing capacity additions


Source: Avendus, Brickwork Ratings, CareEdge Ratings, Data as on 31<sup>st</sup> December, 2025, F – Forecasted; “Market size (USD billion)” for India’s private hospital sector refers to the total annual revenue generated by private hospitals within India, including all patient care and related services, converted from INR to USD. This figure excludes public hospital revenues and is a measure of domestic private hospital consumption.; P – Projected; above bed expansion and operational beds graph includes Sample set of listed 9 Players.

# Healthcare Research, Analytics, Medical Equipment & Supplies

## Medical Devices Market in India (2024-30, in US\$ billion)




## Indian diagnostics industry (Rs. Billion)




Foreign investment in medical devices is rising, and healthcare analytics globally is set for strong long-term growth


# Healthcare Service Providers: Laboratories, Diagnostic Services




Net Sales Growth of India's Diagnostic Services Market (%)



PBILD Margin of India's Diagnostic Services Market (%)




India Diagnostic Labs Market Forecast



FY21–22 saw exceptional growth with ~32% surge in net sales and PBILD margins at 29–32%, driven by pandemic testing. Post-COVID, growth and margins normalized, but structural growth remains strong.

# Contract Research & Manufacturing: India's Edge

Indian CRDMO industry has potential to grow to \$22-25Bn by 2035



Source: BCG + IPSO: UNLEASHING THE TIGER Indian CRDMO Sector – 2025, Data as on 31<sup>st</sup> December, 2025. Note: CRDMO market includes Early Biology, Drug Discovery, Discovery Biology, DMPK & Toxicology, Bioanalytics/Biomarkers, and CDMO for Small Molecules, Biologics & New Modalities. Excludes Gx CDMO, Drug Product CDMO, Clinical Trials, Disease models and Clinical Toxicology Source: Customer interviews, Customer survey Feb'25 (N=200), BCG analysis; SM – Small Molecules; CRDMO – Contract Research, Development, and Manufacturing Organization

## Capture Whitespaces

India can build the right talent pool & scale up nascent capabilities to benefit from geopolitical tailwinds

## Continuing the Current Momentum

India continues to maintain the advantage in SM discovery chemistry & scale manufacturing & solve talent issues



CDMO



CRO

# Government Initiatives & Healthcare Spend

Government allocated ₹99,858 crore (US\$11.5 billion) to healthcare in Union Budget 2025–26, a 9.78% increase from FY25



India-UK FTA (July 2025) introduced zero tariffs on 99% of pharma exports, boosting Indian drug access to UK markets.

Trade

Budget

1 2

3 4

Digital

Coverage


Under PM-JAY, Bihar achieved 100% coverage of eligible families, saving ₹1,000 crore in out-of-pocket expenses; 41 crore Ayushman Cards issued nationwide by July 2025.




ABDM progress: 73.98 crore ABHA accounts, 49.06 crore health records linked, 3.63 lakh facilities registered, and 1.59 lakh facilities using ABDM-enabled software as of Feb 2025.

# Underpenetration = Scope for Growth

Total Healthcare Expenditure as % of GDP




Medical Doctors per 10K Population (2025)




India's low healthcare spend and doctor density compared to global peers indicate significant scope for future growth

# Favourable Domestic Market Demographics

## Medical Tourists (in Lakhs)



## Increasing Ageing Population with Increased Life Expectancy



- Ageing population requiring increased medical attention on a steady rise
- 65+ population projected to reach ~11 Cr by 2026
- Life expectancy at birth: ↑ from ~70.0 yrs in 2020 → 72.5 yrs in 2025


# Nifty500 Healthcare Index

---

# Index Methodology : Nifty500 Healthcare Index



# Nifty500 Healthcare Index: Industry Composition by Weightage



Source: Nifty Indices Pvt.Ltd. Data as on Dec 31, 2025. The data shown above pertains to the index and does not in any manner indicate performance of any scheme of the Fund. Historical portfolio of the index has been created and rebalanced periodically based on market data present on those concerned historical periods, which is captured by the index portfolio changes and performance metrics. No additional performance or portfolio assumptions have been made by the AMC.

## Comparison of investment options in healthcare

Basic Industry	Nifty500 Healthcare Index (%)	Nifty Healthcare Index (%)	BSE Healthcare Index (%)	Actively Managed Healthcare Funds (%)
Pharmaceuticals	<b>74.2</b>	78.8	75.1	67.9
Hospital	<b>21.9</b>	20.0	20.4	17.0
Healthcare Service Provider	<b>1.8</b>	-	1.9	3.3
Healthcare Research Analytics & Technology	<b>1.5</b>	1.3	1.5	0.8
Medical Equipment & Supplies	<b>0.6</b>	-	0.6	0.6

AMFI Market cap Classification	Nifty500 Healthcare Index (%)	Nifty Healthcare Index (%)	BSE Healthcare Index (%)	Actively Managed Healthcare Funds (%)
Large cap	<b>46.7</b>	62.8	45.5	35.2
Mid cap	<b>31.7</b>	34.9	27.7	25.6
Small cap	<b>21.6</b>	2.3	26.8	39.2
No. of Stocks	<b>50</b>	20	119	37 (Avg.)

Source: Asia Indices Pvt.Ltd. Data as on Dec 31, 2025; **Past performance may or may not sustain in future.** The index return is in Total Return Variant. The data shown above pertains to the index and does not in manner indicate performance of any scheme of the Fund. Historical portfolio of the index has been created and rebalanced periodically based on market data present on those concerned historical periods, which is captured by the index portfolio changes and performance metrics. No additional performance or portfolio assumptions have been made by the AMC.. Industry Classification is as per AMFI classification. \*Pursuant to Clause 2.7 of Part IV of SEBI Master Circular the universe of "Large Cap" shall consist of top 100 companies, "Mid Cap" shall consist of 101st to 250th company, "Small Cap" shall consist of 251st and onwards companies in terms of full market capitalization.

# Nifty500 Healthcare Index: Periodic Performance & Volatility

Periodic Performance			
Period	Nifty500 Healthcare Index	Nifty 500 Index	Nifty Healthcare Index
Since Inception	<b>16.2%</b>	12.5%	14.7%
15 Years	<b>13.9%</b>	12.3%	12.4%
10 Years	<b>10.8%</b>	14.8%	9.1%
7 Years	<b>17.4%</b>	15.8%	16.8%
5 Years	<b>14.5%</b>	16.9%	14.8%
3 Years	<b>24.2%</b>	16.7%	23.1%
1 Year	<b>-2.0%</b>	7.8%	-1.5%
6 Months	<b>-0.2%</b>	1.5%	1.5%
3 Months	<b>1.8%</b>	5.1%	3.5%

Periodic Volatility			
Period	Nifty500 Healthcare Index	Nifty 500 Index	Nifty Healthcare Index
Since Inception	<b>17.4%</b>	22.0%	18.5%
15 Years	<b>15.9%</b>	16.1%	17.0%
10 Years	<b>16.5%</b>	16.0%	17.7%
7 Years	<b>16.4%</b>	17.2%	17.5%
5 Years	<b>14.1%</b>	14.3%	15.1%
3 Years	<b>13.2%</b>	12.8%	14.0%
1 Year	<b>14.9%</b>	13.3%	15.4%
6 Months	<b>10.9%</b>	8.5%	11.7%
3 Months	<b>9.2%</b>	8.0%	9.6%

Source: Nifty Indices Pvt.Ltd. Data as on Dec 31, 2025; **Past performance may or may not sustain in future.** The index return is in Total Return Variant. The data shown above pertains to the index and does not in manner indicate performance of any scheme of the Fund. Historical portfolio of the index has been created and rebalanced periodically based on market data present on those concerned historical periods, which is captured by the index portfolio changes and performance metrics. No additional performance or portfolio assumptions have been made by the AMC... The returns more than 1 Year are CAGR returns and below 1 Year returns are absolute returns

# Nifty500 Healthcare Index: Calendar Year Performance

Calendar Year	Nifty500 Healthcare Index	Nifty 500 Index	Nifty Healthcare Index
2010	<b>37.0%</b>	15.3%	36.6%
2011	<b>-14.2%</b>	-26.4%	-11.7%
2012	<b>36.6%</b>	33.5%	33.9%
2013	<b>16.9%</b>	4.8%	21.9%
2014	<b>50.0%</b>	39.3%	47.6%
2015	<b>22.4%</b>	0.2%	12.9%
2016	<b>-8.8%</b>	5.1%	-13.2%
2017	<b>2.9%</b>	37.7%	-1.9%
2018	<b>-3.3%</b>	-2.1%	-5.2%
2019	<b>-4.6%</b>	9.0%	-5.9%
2020	<b>63.6%</b>	17.9%	57.9%
2021	<b>19.0%</b>	31.6%	19.1%
2022	<b>-13.6%</b>	4.2%	-10.1%
2023	<b>38.3%</b>	26.9%	34.0%
2024	<b>41.4%</b>	16.2%	41.4%
2025	<b>-2.0%</b>	7.8%	-1.5%

Source: Nifty Indices Pvt.Ltd. Data as on Dec 31, 2025; **Past performance may or may not sustain in future.** The index return is in Total Return Variant. The data shown above pertains to the index and does not in manner indicate performance of any scheme of the Fund. Historical portfolio of the index has been created and rebalanced periodically based on market data present on those concerned historical periods, which is captured by the index portfolio changes and performance metrics. No additional performance or portfolio assumptions have been made by the AMC. The Calendar Year returns are absolute returns

# Comparison of Nifty500 Healthcare Index v/s Active Healthcare Funds

Actively Managed Healthcare Funds – Direct Plan Growth							
Particular	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years	5 Years
<b>Nifty500 Healthcare Index</b>	-2.2%	1.8%	-0.2%	-2.0%	17.7%	24.2%	14.5%
<b>Average of the category</b>	-2.3%	1.5%	-0.2%	-2.6%	17.6%	23.9%	16.3%
No of funds underperforming	8	10	6	10	7	6	1
Count of Total funds	17	16	16	15	12	9	8
<b>% of funds under-performing the index</b>	47%	63%	38%	67%	58%	67%	13%

Actively Managed Healthcare Funds – Regular Plan Growth							
Particular	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years	5 Years
<b>Nifty500 Healthcare Index</b>	-2.2%	1.8%	-0.2%	-2.0%	17.7%	24.2%	14.5%
<b>Average of the category</b>	-2.4%	1.2%	-0.7%	-3.9%	16.1%	22.3%	14.9%
No of funds underperforming	9	10	8	12	10	8	2
Count of Total funds	16	15	15	15	12	9	8
<b>% of funds under-performing the index</b>	56%	67%	53%	80%	83%	89%	25%

**Nifty500 Healthcare Index has been able to outperform active healthcare funds historically for both regular and direct plans**

# Nifty500 Healthcare Index Portfolio

Sr. No.	Security Name	Basic Industry	Weightage	Sr. No.	Security Name	Basic Industry	Weightage
1	SUN PHARMACEUTICAL INDUSTRIES LTD.	Pharmaceuticals	10.0%	26	SYNGENE INTERNATIONAL LTD.	Healthcare Research Analytics & Tech.	1.0%
2	CIPLA LTD.	Pharmaceuticals	7.2%	27	WOCKHARDT LTD.	Pharmaceuticals	1.0%
3	DIVI'S LABORATORIES LTD.	Pharmaceuticals	6.9%	28	AJANTA PHARMACEUTICALS LTD.	Pharmaceuticals	1.0%
4	MAX HEALTHCARE INSTITUTE LTD.	Hospital	6.6%	29	DR. LAL PATH LABS LTD.	Healthcare Service Provider	1.0%
5	DR. REDDY'S LABORATORIES LTD.	Pharmaceuticals	6.5%	30	PIRAMAL PHARMA LTD.	Pharmaceuticals	0.9%
6	APOLLO HOSPITALS ENTERPRISE LTD.	Hospital	6.1%	31	GSK PHARMACEUTICALS LTD.	Pharmaceuticals	0.9%
7	LUPIN LTD.	Pharmaceuticals	4.3%	32	GLOBAL HEALTH LTD.	Hospital	0.8%
8	FORTIS HEALTHCARE LTD.	Hospital	3.9%	33	ONESOURCE SPECIALTY PHARMA LTD.	Pharmaceuticals	0.8%
9	LAURUS LABS LTD.	Pharmaceuticals	3.6%	34	GRANULES INDIA LTD.	Pharmaceuticals	0.7%
10	TORRENT PHARMACEUTICALS LTD.	Pharmaceuticals	3.4%	35	JUBILANT PHARMOVA LTD.	Pharmaceuticals	0.7%
11	AUROBINDO PHARMA LTD.	Pharmaceuticals	2.8%	36	COHANCE LIFESCIENCES LTD.	Pharmaceuticals	0.7%
12	ALKEM LABORATORIES LTD.	Pharmaceuticals	2.7%	37	ERIS LIFESCIENCES LTD.	Pharmaceuticals	0.7%
13	GLENMARK PHARMACEUTICALS LTD.	Pharmaceuticals	2.6%	38	NATCO PHARMA LTD.	Pharmaceuticals	0.7%
14	MANKIND PHARMA LTD.	Pharmaceuticals	2.1%	39	PFIZER LTD.	Pharmaceuticals	0.6%
15	BIOCON LTD.	Pharmaceuticals	2.0%	40	POLY MEDICURE LTD.	Medical Equipment & Supplies	0.6%
16	ZYDUS LIFESCIENCES LTD.	Pharmaceuticals	1.9%	41	RAINBOW CHILDRENS MEDICARE LTD.	Hospital	0.6%
17	IPCA LABORATORIES LTD.	Pharmaceuticals	1.7%	42	ASTRAZENCA PHARMA INDIA LTD.	Pharmaceuticals	0.5%
18	ABBOTT INDIA LTD.	Pharmaceuticals	1.3%	43	INDEGENE LTD.	Healthcare Research Analytics & Tech.	0.5%
19	KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD.	Hospital	1.3%	44	VIJAYA DIAGNOSTIC CENTRE LTD.	Healthcare Service Provider	0.4%
20	J.B. CHEMICALS & PHARMACEUTICALS LTD.	Pharmaceuticals	1.3%	45	METROPOLIS HEALTHCARE LTD.	Healthcare Service Provider	0.4%
21	ASTER DM HEALTHCARE LTD.	Hospital	1.2%	46	ALEMBIC PHARMACEUTICALS LTD.	Pharmaceuticals	0.4%
22	GLAND PHARMA LTD.	Pharmaceuticals	1.2%	47	CONCORD BIOTECH LTD.	Pharmaceuticals	0.4%
23	NEULAND LABORATORIES LTD.	Pharmaceuticals	1.1%	48	EMCURE PHARMACEUTICALS LTD.	Pharmaceuticals	0.3%
24	NARAYANA HRUDAYALAYA LTD.	Hospital	1.1%	49	DR. AGARWAL'S HEALTH CARE LTD.	Hospital	0.3%
25	SAI LIFE SCIENCES LTD.	Pharmaceuticals	1.1%	50	CAPLIN POINT LABORATORIES LTD.	Pharmaceuticals	0.3%

Source: Nifty Indices Pvt.Ltd. Data as on Dec 31, 2025.

## Why consider investing in Mirae Asset Nifty 500 Healthcare ETF?

---

- Seek to gain diversified exposure across pharma (74%), hospitals (22%), diagnostics, med-tech, and healthcare tech via the Nifty500 Healthcare Index (refer slide no. 18).
- Invests into healthcare segments growing at double digit CAGRs backed by favourable demographics, under penetration and renewed focus by government and masses.
- Tailwinds from ageing population, higher government healthcare spending, medical tourism, and India's pharma exports.
- A relatively low-cost option to participate in India's healthcare story across market cap segments.

# New Fund Offering (NFO) Details

Particulars	Mirae Asset Nifty 500 Healthcare ETF
NFO Period	27 <sup>th</sup> January, 2026 – 06 <sup>th</sup> February, 2026
Type of Scheme	An open-ended scheme replicating/tracking Nifty500 Healthcare Total Return Index
Benchmark	Nifty500 Healthcare Index
Scheme reopens	11 <sup>th</sup> February, 2026
Listing Date	Within 5 working/business days from the date of allotment
Fund Manager	Ms. Ekta Gala & Mr. Ritesh Patel
Minimum Investment during NFO	Rs. 5000/- and in multiples of Re. 1/- thereafter.
Exit Load	Nil

## PRODUCT LABELLING

---

**Mirae Asset Nifty 500 Healthcare ETF is suitable for investors who are seeking\***


- Returns that are commensurate with the performance of Nifty 500 Healthcare Total Return Index, subject to tracking error over long term.
- Investment in securities constituting in Nifty 500 healthcare Total Return Index.

\*Investors should consult their financial advisors if they are not clear about the suitability of the product.

**Scheme Riskometer**



**Scheme Benchmark: Nifty 500 healthcare Total Return Index Benchmark Riskometer**



# Disclaimers

The information contained in this document is compiled from third party and publicly available sources and is included for general information purposes only. There can be no assurance and guarantee on the yields. Views expressed by the Fund Manager cannot be construed to be a decision to invest. The statements contained herein are based on current views and involve known and unknown risks and uncertainties. Whilst Mirae Asset Investment Managers (India) Private Limited (the AMC) shall have no responsibility/liability whatsoever for the accuracy or any use or reliance thereof of such information. The AMC, its associate or sponsors or group companies, its Directors or employees accepts no liability for any loss or damage of any kind resulting out of the use of this document. The recipient(s) before acting on any information herein should make his/her/their own investigation and seek appropriate professional advice and shall alone be fully responsible / liable for any decision taken on the basis of information contained herein. Any reliance on the accuracy or use of such information shall be done only after consultation to the financial consultant to understand the specific legal, tax or financial implications.

**DISCLAIMER OF NSE:** As required, a copy of this Scheme Information Document has been submitted to National Stock Exchange of India Limited (hereinafter referred to as NSE). NSE has given vide its letter NSE/LIST/5913 dated September 17, 2025 permission to the Mutual Fund to use the Exchange's name in this Scheme Information Document as one of the stock exchanges on which the Mutual Fund's units are proposed to be listed subject to, the Mutual Fund fulfilling various criteria for listing. The Exchange has scrutinized this Scheme Information Document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to the Mutual Fund. It is to be distinctly understood that the aforesaid permission given by NSE should not in any way be deemed or construed that the Scheme Information Document has been cleared or approved by NSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of this Scheme Information Document; nor does it warrant that the Mutual Fund's units will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of the Mutual Fund, its sponsors, its management or any scheme of the Mutual Fund. Every person who desires to apply for or otherwise acquire any units of the Mutual Fund may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.

**DISCLAIMER OF BSE:** "BSE Ltd. ("the Exchange") has given vide its letter no. LO/IPO/AB/MF/IP/40/2025-26 dated September 17, 2025 permission to use the Exchange's name in this SID as one of the Stock Exchanges on which this Mutual Fund's Units are proposed to be listed. The Exchange has scrutinized this SID for its limited internal purpose of deciding on the matter of granting the aforesaid permission to. The Exchange does not in any manner: - i) ii) iii) warrant, certify or endorse the correctness or completeness of any of the contents of this SID; or warrant that this scheme's units will be listed or will continue to be listed on the Exchange; or take any responsibility for the financial or other soundness of this Mutual Fund, its promoters, its management or any scheme or project of this Mutual Fund; and it should not for any reason be deemed or construed that this SID has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any unit of this Fund may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription/ acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.

**NSE Indices Ltd Disclaimer:** NSE Indices Ltd Disclaimer: NSE INDICES LIMITED do not guarantee the accuracy and/or the completeness of the Nifty500 Healthcare Index or any data included therein and NSE INDICES LIMITED shall have not have any responsibility or liability for any errors, omissions, or interruptions therein. NSE INDICES LIMITED does not make any warranty, express or implied, as to results to be obtained by the Issuer, owners of the product(s), or any other person or entity from the use of the Nifty500 Healthcare Index or any data included therein. NSE INDICES LIMITED makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the index or any data included therein. Without limiting any of the foregoing, NSE INDICES LIMITED expressly disclaim any and all liability for any claims, damages or losses arising out of or related to the Products, including any and all direct, special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such damages.

**Mutual fund investments are subject to market risks, read all scheme related documents carefully.**

For further information about other schemes (product labelling and performance of the fund) please visit the website of the AMC: [www.miraeassetmf.co.in](http://www.miraeassetmf.co.in)

**Please consult your financial advisor or mutual fund distributor before investing**

THANK YOU

